Wednesday, November 26, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Goldman Sachs Analyst Maintains Buy Rating for Nutrien with Lowered Price Target

Elaine Mendonca by Elaine Mendonca
February 1, 2024
in Breaking News
0
Finance_Budgeting (1)
0
SHARES
4
VIEWS
Share on FacebookShare on Twitter

On February 1, 2024, Adam Samuelson, an analyst at Goldman Sachs, reaffirmed his positive sentiment towards Nutrien (NTR) by maintaining a Buy rating. However, he did make an adjustment to the price target, lowering it from $88 to $78. This adjustment aligns with the median target of $75.00 suggested by a group of 23 analysts.

Although the price target has decreased, the Buy rating still signifies an optimistic outlook for Nutrien’s stock. It is crucial for investors to take into account the diverse range of analyst recommendations and price targets in order to make well-informed investment decisions.

NTR (Nutrien Ltd.) Stock Performance Shows Positive Signs with 2.17% Rise: Potential Undervaluation or Challenges?

On February 1, 2024, the stock performance of NTR (Nutrien Ltd.) showed some positive signs with a 2.17% rise in price since the market last closed. NTR opened at $50.36, which was $0.49 higher than its previous close, indicating some positive sentiment surrounding the stock at the opening of the market. The stock was trading near the bottom of its 52-week range, suggesting potential undervaluation or challenges. Investors and analysts would have closely monitored NTR’s stock throughout the day to assess its future performance.

NTR Stock Performance on February 1, 2024: Mixed Results with Strong Revenue Growth but Decline in Net Income and EPS

NTR Stock Performance on February 1, 2024:

Total Revenue:
– NTR reported a total revenue of $37.88 billion over the past year, a 36.71% increase compared to the previous year.
– However, when compared to the previous quarter’s figure of $5.63 billion, there was a significant decline of 51.68%.

Net Income:
– NTR reported a net income of $7.66 billion over the past year, a substantial increase of 142.94%.
– The net income for the most recent quarter, Q3, stood at $75.00 million, indicating a decline of 82.95% compared to the previous quarter.

Earnings per Share:
– NTR’s EPS over the past year was reported at $14.18, a significant increase of 157.01%.
– The EPS for the most recent quarter, Q3, was reported at $0.15, representing a decline of 82.92% compared to the previous quarter.

Overall, NTR’s stock performance on February 1, 2024, showcased a mixed picture. While the company experienced substantial growth in total revenue, net income, and EPS over the past year, the most recent quarter’s figures indicated a decline across these key financial metrics. Investors should carefully analyze the reasons behind the decline before making investment decisions.

Tags: NTR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Real Estate Investment Markets and money

Analyst Maintains Positive Outlook on DR Horton with Revised Price Target

Corbus Pharmaceuticals Raises Funds for Clinical Development and Faces Market Fluctuations

Diana Shipping Inc Secures Major Time Charter Contract with Nippon Yusen Kabushiki Kaisha

Recommended

Vanda Pharmaceuticals Receives FDA Approval for Investigational New Drug VTR297

2 years ago
Eli Lilly Stock

Eli Lilly Faces Pricing Pressure as New Regulations Force Strategic Shift

3 months ago
Robinhood Stock

Robinhood’s Prediction Markets Hit $4 Billion Trading Milestone

2 months ago
Caribou Biosciences Stock

Caribou Biosciences Stock: Navigating a Critical Juncture

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials NIO Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Volatus Aerospace Secures Major Funding Injection

Tilray Stock: Is a Major Rally Underway?

Hims & Hers Stock Surges on Strategic Expansion into Hormone Diagnostics

Netflix Shares Dip as Takeover Battle Intensifies

Bionxt Solutions Shares: A Pivotal Moment Approaches

Broadcom’s AI Ascent: The Quiet Powerhouse Challenging Nvidia

Trending

Pfizer Stock
Analysis

Pfizer’s Breakthrough Vaccine Data Sparks Market Optimism

by Felix Baarz
November 26, 2025
0

Pfizer is making significant strides in reshaping its post-pandemic trajectory, with recent clinical trial results generating substantial...

Keurig Dr Pepper Stock

Keurig Dr Pepper’s Strategic Gambit: A Path to Recovery?

November 26, 2025
Nike Stock

Nike Shares Show Signs of Life After Prolonged Downturn

November 26, 2025
Volatus Aerospace Stock

Volatus Aerospace Secures Major Funding Injection

November 26, 2025
Tilray Stock

Tilray Stock: Is a Major Rally Underway?

November 26, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Pfizer’s Breakthrough Vaccine Data Sparks Market Optimism
  • Keurig Dr Pepper’s Strategic Gambit: A Path to Recovery?
  • Nike Shares Show Signs of Life After Prolonged Downturn

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com